A former senior executive at Madrigal Pharmaceuticals has sued the company in federal court, alleging he was forced out after warning top leaders about liver-injury data tied to Rezdiffra, the first FDA-approved drug for the liver disease MASH. Michael Charlton, a physician who led clinical development from October 2024 until January 2026, filed the retaliation lawsuit on Oct. 9 in the U.S. District Court for the Northern District of Illinois, STAT reported.
Madrigal vigorously denies the accusations and defends the drug's safety, according to STAT. None of the claims has been tested in court, and no regulatory action tied to them has been announced.